Addressing the Research and Development Gaps in Modern Phage Therapy
PHAGE: Therapy, Applications, and Research · 01.03.2024 · 5 (1) · 30-39
DOI: 10.1089/phage.2023.0045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PHAGE: Therapy, Applications, and Research, online erschienen am 18.03.2024. Verfasst von Paul E Turner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance is on the rise globally, prompting increased research and development (R&D) of phage therapy as a strategy to address difficult-to-treat bacterial infections. We review the current state of phage therapy research, including major operational, epistemic, and biological challenges for phage R&D, and discuss some new approaches to developing the technology motivated by recent breakthroughs such as artificial intelligence and synthetic phage production. In addition, we contextualize these R&D challenges and opportunities in light of the ongoing predicament of commercial antimicrobial innovation and current public–private efforts to reinvigorate the pipeline of antimicrobial drug discovery. We conclude with reflections on the potential for new phage therapies to be readily accessible across all income contexts to better ensure broad patient access, and consider possible alternatives to current public and public–private solutions for phage therapy and production.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut, USA.
- Microbiology Program, Yale University School of Medicine, New Haven, Connecticut, USA.
- Center for Phage Biology and Therapy, Yale University, New Haven, Connecticut, USA.
- Centre of Biological Engineering, University of Minho, Braga, Portugal.
- LABBELS-Associate Laboratory, Braga, Guimarães, Portugal.
- CARB-X, Boston University, Boston, Massachusetts, USA.
ORCID-Profile: Sabrina Green
Zitieren
APA
Turner, P. E., Azeredo, J., Buurman, E. T., Green, S., Haaber, J. K., Haggstrom, D., Kameda de Figueiredo Carvalho, K., Kirchhelle, C., Gonzalez Moreno, M., Pirnay, J. P., & Portillo, M. A. (2024). Addressing the Research and Development Gaps in Modern Phage Therapy. PHAGE: Therapy, Applications, and Research, 5(1), 30-39. https://doi.org/10.1089/phage.2023.0045
Vancouver
Turner PE, Azeredo J, Buurman ET, Green S, Haaber JK, Haggstrom D, et al. Addressing the Research and Development Gaps in Modern Phage Therapy. PHAGE: Therapy, Applications, and Research. 2024;5(1):30-39. doi:10.1089/phage.2023.0045
BibTeX
@article{Turner2024,
author = {Turner, Paul E and Azeredo, Joana and Buurman, Ed T and Green, Sabrina and Haaber, Jakob Krause and Haggstrom, Douglas and Kameda de Figueiredo Carvalho, Koichi and Kirchhelle, Claas and Gonzalez Moreno, Mercedes and Pirnay, Jean-Paul and Portillo, Mirza Alas},
title = {Addressing the Research and Development Gaps in Modern Phage Therapy},
journal = {PHAGE: Therapy, Applications, and Research},
year = {2024},
volume = {5},
number = {1},
pages = {30--39},
doi = {10.1089/phage.2023.0045}
}
EUVIMED